Prestige Consumer Healthcare Inc.
PBHPrestige Consumer Healthcare Inc. (formerly Prestige Brands, Inc.) is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York: 2 and operates a manufacturing facility in Lynchburg, Virginia.: 9
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
4wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How PBH's past catalysts played out
HD204
Lung Cancer
HD201
HER2 Positive Breast Cancer
PBP1510 (400mg/16mL)
Pancreatic Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HD204 | Phase 3 | Lung Cancer | - | - |
HD201 | Phase 3 | HER2 Positive Breast Cancer | - | - |
PBP1510 (400mg/16mL) | Phase 2 | Pancreatic Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Prestige Consumer Healthcare Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Prestige Consumer Healthcare Inc.'s (PBH) pipeline across Phase 3, Phase 2. Its lead program is HD204 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Prestige Consumer Healthcare Inc.'s next FDA catalyst?→
Prestige Consumer Healthcare Inc.'s (PBH) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PBH biotech catalysts?→
Add PBH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Prestige Consumer Healthcare Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.